Vital Signs - CETP Inhibitors Promising Treatments in Development for Dyslipidemia
Vital Signs - CETP Inhibitors Promising Treatments in Development for Dyslipidemia
RELEASE DATE
17-Jan-2011
17-Jan-2011
REGION
North America
North America
Research Code: 9561-00-B8-00-00
SKU: HC00613-NA-MR_04086
$1,500.00
Special Price $1,125.00 save 25 %
In stock
SKU
HC00613-NA-MR_04086
Description
This issue of Vital Signs, released on January 17, 2011, provides a strategic overview of CETP inhibitor treatments in development for dyslipidemia. Additionally, a company spotlight is provided for DARA BioSciences, a development stage biopharmaceutical company. Reimbursement and regulatory news from the FDA is also provided for the week of December 26, 2010.
Table of Contents
This week's issue
Popular Topics
This issue of Vital Signs, released on January 17, 2011, provides a strategic overview of CETP inhibitor treatments in development for dyslipidemia. Additionally, a company spotlight is provided for DARA BioSciences, a development stage biopharmaceutical company. Reimbursement and regulatory news from the FDA is also provided for the week of December 26, 2010.
No Index | Yes |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | 9561-00-B8-00-00 |
Is Prebook | No |